We have continued this thread of investigation by evaluating the validity of theRodnan Scleroderma Skin Score (a primary outcome in generalized scleroderma studies) and the Raynaud’s Condition Score (the primary outcome for all raynauds clinical trials). We have conducted a number of investigations of potential treatments including “d-Penicillamine”, “Relaxin” for generalized, diffuse scleroderma, “dasatimib” for pulmonary fibrosis in diffuse scleroderma, and“scleroderma treatment strategies”. In 2015 – 2017 we were the second largest center in Cytori STAR Study. This evaluated the effectiveness of injection of autologously harvested fat stem cells into the fingers of patients with scleroderma related hand contractures. In 2016-8 we participated in the FocuSSCed Study. This evaluated subcutaneous Actemra, an FDA approved treatment for RA, in early diffuse scleroderma.
We have also participated in the design and conduct of several studies of potential therapies for raynauds phenomenon: “oral iloprost“, “Vascana”, and “PF-00489791”. October 2019 we commence the AURORA Study which evaluates the effect of intravenous iloprost for symptomatic raynauds in scleroderma.